Clinical utility of fixed combinations of sitagliptin&ndash;metformin in treatment of type 2 diabetes

Código QR

Clinical utility of fixed combinations of sitagliptin&ndash;metformin in treatment of type 2 diabetes

Karen Barnard1,2, Mary Elizabeth Cox1, Jennifer B Green1,21Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Nutrition, Duke University Medical Center, Durham, NC, USA; 2Department of Medicine, Division of Endocrinology, Durham Veterans Affairs Medical Center, Durham, NC, U...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Karen Barnard, Mary Elizabeth Cox, Jennifer B Green
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/6927147c9be3449c808246b19776356e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Jonathan K Reynolds
Publicado: (2009)

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
por: Fleming JW, et al.
Publicado: (2015)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Robert Moses
Publicado: (2009)

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
por: Maffioli P, et al.
Publicado: (2011)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Shannon A Miller, et al.
Publicado: (2009)

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
por: Robert G Moses
Publicado: (2010)

Long-term (52&ndash;78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients
por: Bays HE
Publicado: (2012)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahr&eacute;n
Publicado: (2010)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto S, et al.
Publicado: (2015)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holl, et al.
Publicado: (2014)

Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial
por: Zhang F, et al.
Publicado: (2021)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker CM, et al.
Publicado: (2016)

Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
por: Moses R
Publicado: (2010)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
por: Schwartz SS, et al.
Publicado: (2016)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
por: Stolar MW, et al.
Publicado: (2013)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review
por: Katrine B Hansen, et al.
Publicado: (2010)

Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
por: Irons BK, et al.
Publicado: (2014)

Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins
por: Di Pierro F, et al.
Publicado: (2015)

Antihyperglycemic, antihyperlipidemic, anti-inflammatory and adenosine deaminase&ndash;lowering effects of garlic in patients with type 2 diabetes mellitus with obesity
por: Kumar R, et al.
Publicado: (2013)

Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated [Corrigendum]
por: Irons BK, et al.
Publicado: (2017)

Prevalence of overweight and obesity in adult Nigerians &ndash; a systematic review
por: Chukwuonye II, et al.
Publicado: (2013)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)

Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
por: Ohira M, et al.
Publicado: (2014)

Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
por: Alexander Sergeevich Ametov, et al.
Publicado: (2010)

Combination of Metformin and Exercise in Management of Metabolic Abnormalities Observed in Type 2 Diabetes Mellitus
por: Jevtovic F
Publicado: (2021)

Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR&reg; TS
por: Przemyslaw Holko, et al.
Publicado: (2011)

The clinical utility of aflibercept for diabetic macular edema
por: Stewart MW
Publicado: (2015)

Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam &ndash; a clinical perspective
por: Ronald B Goldberg
Publicado: (2009)

Metformin and Malignant Tumors: Not Over the Hill [Response to Letter]
por: Leng W, et al.
Publicado: (2021)

Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity
por: Bruckbauer A, et al.
Publicado: (2013)

Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
por: Shin JH, et al.
Publicado: (2013)

Guidelines in the management of diabetic nerve pain clinical utility of pregabalin
por: Vinik AI, et al.
Publicado: (2013)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud A, et al.
Publicado: (2015)

Insulin, but Not Metformin, Supports Wound Healing Process in Rats with Streptozotocin-Induced Diabetes
por: Mieczkowski M, et al.
Publicado: (2021)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
por: Seufert J
Publicado: (2015)

Curcumin improves prostanoid ratio in diabetic mesenteric arteries associated with cyclooxygenase-2 and NF-&kappa;B suppression
por: Sirada Rungseesantivanon, et al.
Publicado: (2010)

Effects of Metformin on the Gut Microbiota in Obesity and Type 2 Diabetes Mellitus
por: Zhang Q, et al.
Publicado: (2020)

Metformin and Malignant Tumors: Not Over the Hill: A Short Comment [Letter]
por: Rastmanesh R
Publicado: (2021)

Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway
por: Civantos E, et al.
Publicado: (2017)